Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain

Published:2021-01-01 Issue:1 Volume:24 Page:874-882
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

González-Barcala Francisco Javier¹²,Muñoz-Gall Xavier³⁴⁵,Mariscal Esther⁶,García Andrea⁶,Yang Shibing⁷,van de Wetering Gijs⁸,Izquierdo-Alonso José Luis⁹

Affiliation:

1. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain

2. Respiratory Medicine, Universidad de Santiago de Compostela, Santiago de Compostela, Spain

3. Department of Pulmonology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

4. CIBER of Respiratory Diseases (CIBERes), Madrid, Spain

5. Cell Biology, Physiology, and Immunology, Universidad Autónoma de Barcelona, Barcelona, Spain

6. GlaxoSmithKline, Madrid, Spain

7. GlaxoSmithKline, Collegeville, PA, USA

8. Pharmerit International, Rotterdam, the Netherlands

9. Medicine and Specialities Department, Universidad de Alcalá (Alcalá de Henares, Madrid), Hospital Universitario Guadalajara, Guadalajara, Spain

Funder

GlaxoSmithKline

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1941065

Reference60 articles.

1. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

2. The global burden of asthma: executive summary of the GINA Dissemination Committee Report

3. Economic impact of severe asthma in Spain: multicentre observational longitudinal study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unanswered questions on the use of biologics in pediatric asthma;World Allergy Organization Journal;2023-11

2. Cost-Effectiveness of Biologic Therapies in Asthma in Spain;Archivos de Bronconeumología;2023-10

3. Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting;Journal of Asthma;2023-08-12

4. Cost-effectiveness of tezepelumab in Canada for severe asthma;Journal of Medical Economics;2023-07-17

5. Economic evaluation of biological treatments in patients with severe asthma: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-09